Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 8

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 8
---
; IHL-675A for the treatment of inflammatory conditions, including rheumatoid arthritis, and PSX-001,
our oral synthetic psilocybin treatment, in combination with psychotherapy, for the treatment of generalized anxiety disorder. Our programs
target disorders that have limited, inadequate, or no approved pharmaceutical treatment options.

To date, we have not
generated any material revenue and do not expect to generate significant revenue from the sale of our drug candidates in development
in the foreseeable future. If our development efforts for our drug candidates are successful and result in regulatory approval, we
may generate revenue in the future from these sales. We cannot predict if, when, or to what extent we will generate revenue from the
commercialization and sale of our drug candidates. We may never succeed in obtaining regulatory approval for any of our drug
candidates.

2025 Private Placement

On March 7, 2025, we
entered into a private placement (the “Private Placement”) pursuant to securities purchase agreements (“March 2025
Purchase Agreements”) with the selling stockholders for the purchase and sale of 9,687,045 shares (the “PIPE
Shares”) of Common Stock for a purchase price of $1.08 per share of Common Stock (and, in lieu thereof, Pre-Funded Warrants to
purchase up to 1,887,045 shares (the “Pre-Funded Warrant Shares”) of Common Stock) at a price of $1.0799 per Pre-Funded
Warrant and Series A Warrants to purchase up to 11,574,090 shares of Common Stock at an initial exercise price of $2.16 per share,
subject to adjustment to up to an aggregate of 347,222,700 shares of Common Stock assuming full adjustment of the exercise price to
the Floor Price (as defined below) and exercise pursuant to the zero exercise price provisions of the Series A Warrants as described
below (the “Series A Warrant Shares” and together with the Pre-Funded Warrant Shares, the “Warrant Shares”).
The PIPE Shares, the Series A Warrants, Series A Warrant Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares are
collectively referred to as the “Securities.”

The Pre-Funded Warrants are
exercisable (in cash or by cashless exercise) for shares of Common Stock for a nominal exercise price of $0.0001 per Pre-Funded Warrant
Share, were immediately